SCHEDULE 13G/A 0001493152-25-013532 0002052389 XXXXXXXX LIVE 1 Ordinary Shares, par value $0.0135 per share 09/11/2025 0002022416 Silexion Therapeutics Corp G1281K130 12 Abba Hillel Road, Ramat Gan, L3 5250606 Rule 13d-1(c) Orca Capital AG 2M 109432.00 0.00 109432.00 0.00 109432.00 N 4.9 CO All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 2,123,892 Ordinary Shares outstanding immediately after giving effect to the completion of the Issuer's registered offering and excludes 153,068 Ordinary Shares issuable upon the exercise of warrants held by the Reporting Person, subject to the 4.99% blocker (defined below). Pursuant to the terms of the warrants, as described in the Issuer's Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on September 12, 2025, the Reporting Person cannot exercise any of the warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 4.99% of the Issuer's outstanding Ordinary Shares (the "4.99% Blocker"). Silexion Therapeutics Corp 12 Abba Hillel Road, Ramat Gan, Israel 5250606 Orca Capital AG Sperlring 2 85276 Hettenshausen Deutschland Germany 109,432 4.9% 109,432 0 109,432 0 N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Orca Capital AG /s/ Thomas Konig 09/15/2025